Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.

doi:10.1093/jac/dkv465

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.

The Journal of antimicrobial chemotherapy - 1 May 2016

De Luca Andrea, Flandre Philippe, Dunn David, Zazzi Maurizio, Wensing Annemarie, Santoro Maria Mercedes, Günthard Huldrych F, Wittkop Linda, Kordossis Theodoros, Garcia Federico, Castagna Antonella, Cozzi-Lepri Alessandro, Churchill Duncan, De Wit Stéphane, Brockmeyer Norbert H, Imaz Arkaitz, Mussini Cristina, Obel Niels, Perno Carlo Federico, Roca Bernardino, Reiss Peter, Schülter Eugen, Torti Carlo, van Sighem Ard, Zangerle Robert, Descamps Diane

Abstract excerpt

OBJECTIVES: The objective of this study was to improve the prediction of the impact of HIV-1 protease mutations in different viral subtypes on virological response to darunavir. METHODS: Darunavir-containing treatment change episodes (TCEs) in patients previously failing PIs were selected from large European databases. HIV-1 subtype B-infected patients were used as the derivation dataset and HIV-1 non-B-infected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Darunavir

Share to Drug Resistance, Viral

Share to Europe

Share to Genotyping Techniques

Share to HIV-1

Share to HIV Infections

Share to HIV Protease

Source

Open in PubMed Open full text

Identifiers

PMID: 26825119
DOI: 10.1093/jac/dkv465
PMCID: PMC5808835

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.PMID 26825119Read ↗

Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.Semantic proximity Read ↗

Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B.Semantic proximity Read ↗

Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).Semantic proximity Read ↗

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.Semantic proximity Read ↗

Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes.Semantic proximity Read ↗

Interpretation of genotypic resistance to predict darunavir/ritonavir failure in antiretroviral experienced patients.Semantic proximity Read ↗

Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients.Semantic proximity Read ↗

Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection.Semantic proximity Read ↗

Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.Semantic proximity Read ↗

Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy.Semantic proximity Read ↗

Drug resistance mutations of HIV type 1 non-B viruses to integrase inhibitors in treatment-naive patients from sub-saharan countries and discordant interpretations.Semantic proximity Read ↗

Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.